title: Erythropoietins should be used according to guidelines.
authors.forename: Matti S
authors.initials: MS
authors.lastname: Aapro
authors.forename: Gunnar
authors.initials: G
authors.lastname: Birgegård
authors.forename: Carsten
authors.initials: C
authors.lastname: Bokemeyer
authors.forename: Paul
authors.initials: P
authors.lastname: Cornes
authors.forename: Jan
authors.initials: J
authors.lastname: Foubert
authors.forename: Pere
authors.initials: P
authors.lastname: Gascon
authors.forename: John
authors.initials: J
authors.lastname: Glaspy
authors.forename: Eva
authors.initials: E
authors.lastname: Hellström-Lindberg
authors.forename: Hartmut
authors.initials: H
authors.lastname: Link
authors.forename: Heinz
authors.initials: H
authors.lastname: Ludwig
authors.forename: Anders
authors.initials: A
authors.lastname: Osterborg
authors.forename: Lazzaro
authors.initials: L
authors.lastname: Repetto
authors.forename: Pierre
authors.initials: P
authors.lastname: Soubeyran
mesh_terms: D000740:Anemia / Q000139:chemically induced / Q000188:drug therapy*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D017277:Drug Approval; D004348:Drug Labeling; D004921:Erythropoietin / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use*; D019983:Guideline Adherence; D006397:Hematinics / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D017410:Practice Guidelines as Topic; D018570:Risk Assessment; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D006397:Hematinics; D004921:Erythropoietin